IDH1 and acute myeloid leukemia: Finally, AML patients with IDH1 mutations have poor overall survival14, 15 and AML patients with IDH2/R172K mutation have lower rates of complete remission and worse prognosis than those with IDH2/R140Q mutations16, 17.